Indication

Cryopyrin-Associated Periodic Syndrome

Cryopyrin-Associated Periodic Syndrome (CAPS) refers to a spectrum of rare, inherited autoinflammatory disorders caused by gain-of-function mutations in the *NLRP3* gene, which encodes the protein cryopyrin. Read more about Cryopyrin-Associated Periodic Syndrome

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common Cryopyrin-Associated Periodic Syndrome therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with Cryopyrin-Associated Periodic Syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Cryopyrin-Associated Periodic Syndrome.

Cryopyrin-Associated Periodic Syndrome (CAPS) refers to a spectrum of rare, inherited autoinflammatory disorders caused by gain-of-function mutations in the *NLRP3* gene, which encodes the protein cryopyrin.

These mutations cause hyperactivation of the NLRP3 inflammasome, precipitating unrestrained, excessive secretion of the proinflammatory cytokine interleukin-1 beta (IL-1ß).

The condition predominantly presents in infancy or early childhood and encompasses a continuum of clinical severity, ranging from familial cold autoinflammatory syndrome to Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease.

Patients experience recurrent or persistent systemic inflammation characterized by periodic fevers, urticaria-like skin rashes, and arthralgias, with more severe manifestations including sensorineural hearing loss, chronic aseptic meningitis, ocular inflammation, skeletal deformities, and secondary amyloidosis.

Personalize your experience

Follow Cryopyrin-Associated Periodic Syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it